Phenylketonuria (PKU) is treated primarily through a strict low-phenylalanine diet that begins within the first days of life and continues for life. The goal is to keep blood phenylalanine levels between 120 and 360 µmol/L, which prevents the brain damage that occurs when phenylalanine builds up unchecked. Beyond diet, some patients benefit from medications that either boost the body’s ability to process phenylalanine or break it down through a different pathway entirely.
How PKU Is Caught Early
Every newborn in the United States is screened for PKU through a simple blood test, typically within 24 to 48 hours of birth. This practice has been in place since the early 1960s. Classical PKU occurs in roughly 1 in every 10,000 to 25,000 newborns in the U.S., with large-scale screening data putting the number closer to 1 in 19,000. Early detection is critical because treatment started in the first weeks of life can prevent intellectual disability almost entirely.
The Low-Phenylalanine Diet
Phenylalanine is an amino acid found in virtually all protein-containing foods. Because people with PKU can’t break it down properly, the cornerstone of treatment is avoiding high-protein foods. The restricted list is long: meat, chicken, fish, eggs, cheese, nuts, seeds, soy, lentils, and grains like wheat, oats, rye, and barley. Even some meat substitutes and the artificial sweetener aspartame (which contains phenylalanine) are off limits.
What remains are mostly fruits, vegetables, fats, sugars, and specially manufactured low-protein versions of bread, pasta, and other staples. The diet is not zero-phenylalanine. Small, carefully measured amounts of natural protein are allowed because the body still needs some phenylalanine as an essential amino acid. The exact amount varies by person and is adjusted based on regular blood tests.
For infants, treatment starts with a phenylalanine-free formula that provides all the amino acids, fats, vitamins, and minerals a baby needs, minus the one amino acid they can’t handle. This formula is given alongside small, controlled amounts of breast milk or standard formula to supply just enough phenylalanine for normal growth. The nutritional profile of these specialized formulas closely mirrors human milk, including fatty acids important for brain development like DHA and arachidonic acid.
Medical Formula for All Ages
The phenylalanine-free amino acid formula isn’t just for babies. People with PKU rely on it throughout their lives as their primary source of protein, vitamins, and minerals, since so many natural protein sources are restricted. For older children and adults, the formula comes in powders, liquids, tablets, and flavored drinks.
One of the biggest complaints about these formulas is taste. Traditional amino acid mixtures tend to be bitter with a strong odor, and this is a major reason people stop following the diet as they get older. A newer option uses a milk-derived protein called glycomacropeptide (GMP), which is naturally very low in phenylalanine. In studies, patients consistently preferred GMP-based foods over traditional amino acid formulas, rating them better tasting and more filling. People on GMP-based diets also reported less persistent hunger and fewer gastrointestinal symptoms compared to standard formulas. GMP can currently replace about half of the protein intake from amino acid supplements.
Medication Options
Some people with PKU respond to a medication that works as a synthetic version of the natural cofactor their enzyme needs to function. In PKU, the enzyme that breaks down phenylalanine is either missing or malfunctioning. This medication gives the enzyme a boost, helping it work more efficiently in patients who still have some residual enzyme activity. About 20% of patients who tried it in clinical trials saw their phenylalanine levels drop by more than 30% within eight days. Response rates varied significantly: among patients with milder forms of PKU (lower baseline phenylalanine levels), more than half responded, while only about 15% of those with more severe forms saw meaningful improvement. Responders can often relax their diet somewhat, though they rarely abandon it completely.
For adults with more severe PKU whose phenylalanine levels remain above 600 µmol/L despite dietary efforts, an enzyme substitution therapy is available as a self-administered injection. This medication works through a completely different mechanism: rather than fixing the broken enzyme, it introduces a substitute enzyme that breaks down phenylalanine through an alternate chemical pathway. It can dramatically lower phenylalanine levels, but it comes with significant side effects. Joint pain affects about 70% of patients, injection site reactions around 62%, and headaches nearly half. The most serious concern is a risk of severe allergic reactions, which led the FDA to require a special safety program. Patients must carry injectable epinephrine and be monitored for at least 60 minutes after each dose during the early treatment phase.
Why Sticking With Treatment Gets Harder
Children with PKU tend to have good dietary adherence, largely because their parents control what they eat. The picture changes dramatically in adolescence and adulthood. A consensus of PKU experts agreed unanimously that the sustainability of dietary treatment worsens starting in early adolescence. In one U.K. survey of 137 adults with PKU, only about 44% always followed the diet, while roughly a quarter had abandoned it entirely.
The reasons are practical and social. Low-protein specialty foods are expensive and hard to find. The amino acid supplements taste unpleasant and need to be consumed multiple times daily. Eating out is complicated, and over 90% of adults with PKU reported confusion with food labeling in the prior six months. The diet also interferes with social life in ways that accumulate over years: shared meals, travel, spontaneous eating are all difficult. This creates a cycle where poor adherence leads to higher phenylalanine levels, which can cause difficulty concentrating, mood changes, and anxiety, all of which make it even harder to maintain the discipline the diet requires.
PKU and Pregnancy
Pregnancy adds another layer of urgency to phenylalanine control. The developing fetus is especially vulnerable because phenylalanine crosses the placenta through an active transport process, meaning fetal blood levels end up even higher than the mother’s. Without strict dietary control, the risks to the baby are severe: a 92% chance of developmental delays, 73% risk of an abnormally small head, and 12% risk of congenital heart defects.
Guidelines from the American College of Obstetricians and Gynecologists recommend that women with PKU bring their phenylalanine levels below 6 mg/dL for at least three months before conception and maintain levels between 2 and 6 mg/dL throughout pregnancy. Achieving this is challenging. One study found that 64% of women at risk were unable to reach target phenylalanine levels by 8 weeks of gestation. When control is achieved before pregnancy or by the eighth week, the risks of fetal complications drop substantially.
Gene Therapy on the Horizon
Several early-stage clinical trials are testing whether gene therapy could offer a more permanent solution for PKU. Two pharmaceutical companies have launched Phase 1 trials in adults, each using a different approach. One delivers a working copy of the phenylalanine-processing gene directly to liver cells using a viral vector. The other attempts to insert a corrective copy of the gene into the exact spot where the original gene sits, so it’s driven by the body’s own regulatory machinery. Both approaches have shown promising results in mouse models of PKU, but human trials are still in their earliest stages, limited to adults ages 15 and older, and no efficacy data from these trials has been published yet.